2002:
PhD, First Faculty of Medicine, Charles University, Prague
1996-2000:
Postdoctoral Fellow, CNRS, Montpellier, France
1994-1996:
Postdoctoral Fellow, NIDCD, NIH, Bethesda, USA
1990:
MD, Second Faculty of Medicine, Charles University, Prague
2003:
Otto Wichterle Award
1998:
Post Rouge, CNRS, France
1997:
Fondation Pour La Recherche Medicale Fellowship, France
1994:
Fogarty International Research Fellowship, NIH, USA
Interaction of SGIP1 with cannabinoid receptor 1 (CB1R) in the brain
We have found that SGIP1 (SH3 domain GRB2-like endophilin-interacting protein 1) modifies the CB1R signalling pathway by interfering with internalization that follows CB1R activation. We also found that SGIP1, like CB1R, concentrates in presynaptic portions of neurons. [pubmed] [doi]
Regulation of the cannabinoid receptor CB1R in vivo by SGIP1
We have tested SGIP1 knockout mice in a battery of behavioural tests. The SGIP1−/− mice did not show changes in sensorimotor gating, exploratory levels, or working memory, but showed decreased anxiety-like symptoms. Our results suggest that the absence of SGIP1 leads to changes in certain behaviours induced by THC administration and CB1R activation. [pubmed] [doi]
Reduction of acute nociception in mice with SGIP1 deletion
We have found that SGIP1-/- mice are more sensitive to analgesics. Our results suggest that SGIP1 is involved in the regulation of emotionality, mood, and nociception and modulates in vivo signalling of CB1 cannabinoid receptors. [pubmed] [doi]